| Literature DB >> 28950897 |
Bo Lv1, Linhui Hu1,2, Lifang Chen1, Bei Hu1, Yanlin Zhang3, Heng Ye4, Cheng Sun1, Xiunong Zhang1, Huilan Lan1, Chunbo Chen5.
Abstract
BACKGROUND: Various special techniques for blind bedside transpyloric tube placement have been introduced into clinical practice. However, transpyloric spiral tube placement facilitated by a blind bedside method has not yet been reported. The objective of this prospective study was to evaluate the safety and efficiency of blind bedside postpyloric placement of a spiral tube as a rescue therapy subsequent to failed spontaneous transpyloric migration in critically ill patients.Entities:
Keywords: Blind bedside; Critically ill patients; Enteral nutrition; Postpyloric placement; Rescue therapy; Spiral nasojejunal tube
Mesh:
Substances:
Year: 2017 PMID: 28950897 PMCID: PMC5615440 DOI: 10.1186/s13054-017-1839-2
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Method of blind bedside postpyloric spiral tube placement. aThe whoosh test was performed by air insufflation with auscultation in the epigastrium, in which a gurgling was regarded as indicative of air entering the stomach while the absence of gurgling suggested the tube tip was located elsewhere (lung, esophagus, pharynx, and so on). bThe vacuum test was done by instilling 60 ml air with a 20-ml syringe three times and then aspirated. If the volume of air aspirated was < 20 ml the tube was likely postpyloric, while if the volume of air aspirated was > 40 ml the tube was likely intragastric. cThe pH test was taken by measuring the pH value of aspiration with a pH strip. Aspiration of pH <5.0 was deemed intragastric. Aspiration of pH 6 − 7 was deemed to be from the small bowel. dThe guide wire withdrawal test was conducted by pulling back the guide wire a little way (within 5 cm). In a coiled tube, the guide wire either could be withdrawn with resistance felt as “popping”, or could be withdrawn easily but was unable to be re-inserted without a degree of force
Clinical and demographic data of patients
| Variables | Values in total study sample |
|---|---|
| Age, years | 60 (48–72) |
| Gender (male) | 86 (67.7) |
| Preexisting diseases | |
| Hypertension | 27 (21.3) |
| Diabetic mellitus | 9 (7.1) |
| Previous gastrointestinal surgery | 4 (3.1) |
| Primary diagnosis | |
| Neurologic | 53 (41.7) |
| Respiratory | 36 (28.4) |
| Cardiovascular | 15 (11.8) |
| Multiple trauma | 14 (11.0) |
| Sepsis | 5 (3.9) |
| Gastrointestinal | 2 (1.6) |
| Others | 2 (1.6) |
| Use of sedatives or analgesics | 22 (11.0) |
| Use of vasopressors | 10 (7.9) |
| Mechanical ventilation | 66 (52.0) |
| APACHE II score | 18 (13–23) |
| SOFA score | 10 (8–12) |
| AGI grade | |
| Without AGI | 5 (3.9) |
| I | 11 (8.7) |
| II | 92 (72.4) |
| III | 19 (15.0) |
Quantitative variables are presented as median (IQR) and qualitative variables as number (percentage)
APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, AGI acute gastrointestinal injury, SD standard deviation, IQR interquartile range
The primary endpoint and secondary efficacy endpoints
| Endpoints | Value in total study sample |
|---|---|
| Primary endpoint | |
| Postpyloric placementa | 104 (81.9) |
| Secondary endpoints | |
| Placed at D3b or beyond | 70 (55.1) |
| Placed at the proximal jejunum | 43 (33.9) |
| Time to insertion, min | 14 (10–15) |
| Number of attempts | 1.4 ± 0.6 |
| Length of insertion, cm | 95.6 ± 9.3 |
Quantitative variables are presented as mean ± SD or median (IQR) as appropriate and qualitative variables as numbers (percentage)
aPostpyloric placement, reaching the first portion of the duodenum or beyond
bD3 is the third portion of the duodenum
Adverse events
| Events, number (percentage) | Value in total study sample (n = 127) |
|---|---|
| Any event | 33 (26.0) |
| MATEs | 29 (22.8) |
| Vital signs alert eventsa | 15 (11.8) |
| Requirement of sedatives or analgesics during procedure | 14 (11.2) |
| Nausea | 8 (6.3) |
| Pain | 6 (4.7) |
| Nasal mucosa bleeding | 5 (3.9) |
| Vomiting | 3 (2.4) |
| Metoclopramide-associated events | 5 (4.0) |
| Amyostasia | 2 (1.6) |
| Lethargy | 1 (0.8) |
| Dysphoria | 1 (0.8) |
| Xerostomia | 1 (0.8) |
Qualitative variables are presented as number (percentage)
MATEs major adverse tube-associated events
aDefined as any vital sign that fluctuated beyond the range of ± 15%, or pulse oxygen saturation that declined to < 90%
Vital signs monitored peri-procedure
| Vital signs | Pre-procedure | Inter-procedurea | Post-procedureb |
| |
|---|---|---|---|---|---|
| Pre-procedure vs. Inter-procedure | Pre-procedure vs. Post-procedure | ||||
| HR (bpm) | 101.3 ± 25.2 | 105.6 ± 25.1 | 102.3 ± 25.2 | <0.0001 | 0.1041 |
| RR (rpm) | 19.0 ± 5.5 | 20.5 ± 5.8 | 19.3 ± 5.3 | <0.0001 | 0.1139 |
| MAP (mmHg) | 97.6 ± 14.0 | 99.9 ± 14.9 | 98.5 ± 14.4 | <0.0001 | 0.1150 |
| SPO2 (%) | 98.6 ± 1.7 | 98.5 ± 1.6 | 98.6 ± 2.0 | 0.0789 | 0.9313 |
Quantitative variables are presented as mean (± SD)
HR heart rate, RR respiratory rate, MAP mean arterial pressure, S O pulse oxygen saturation, bpm beats per minute, rpm respirations per minute
aInter-procedure, data were collected at the widest fluctuation point during the procedure
bPost-procedure, data were collected 30 min after the procedure